论文部分内容阅读
目的探讨VEGF、CA125和CA72-4联合检测在卵巢癌诊断中的应用价值。方法诊断明确的卵巢癌患者68例、卵巢良性肿瘤患者45例以及正常对照40例,血清VEGF检测采用ELISA法,CA125、CA72-4采用美国ARCHITECT i2000SR免疫分析仪检测;利用ROC曲线评价3种指标单独和联合检测诊断卵巢癌的效能。结果卵巢癌患者血清VEGF、CA125、CA72-4表达均高于卵巢良性肿瘤组和正常对照组(P<0.05)。ROC曲线分析:VEGF、CA125、CA72-4诊断卵巢癌的曲线下面积(AUC)分别是0.792,0.834,0.711,3项指标联合的AUC是0.921,3项指标联合检测的AUC大于单项检测(P<0.05)。单项检测中CA125敏感性(69.2%)最高,CA72-4的特异性(88.2%)最好,3项指标联合检测的敏感性和特异性分别为81.0%和84.7%。结论 VEGF、CA125、CA72-4三种指标联合检测能有效提高卵巢癌诊断的准确度。
Objective To investigate the value of combined detection of VEGF, CA125 and CA72-4 in the diagnosis of ovarian cancer. Methods 68 patients with ovarian cancer, 45 patients with benign ovarian tumor and 40 normal controls were enrolled in this study. Serum VEGF was detected by ELISA, CA125 and CA72-4 were detected by ARCHITECT i2000SR immunoassay analyzer. The ROC curve was used to evaluate the three indexes Individual and combined testing to diagnose ovarian cancer. Results The serum levels of VEGF, CA125 and CA72-4 in ovarian cancer patients were significantly higher than those in benign ovarian tumors and normal controls (P <0.05). ROC curve analysis: The area under the curve (AUC) of VEGF, CA125 and CA72-4 in the diagnosis of ovarian cancer were 0.792, 0.834 and 0.711, respectively. The AUC of the three indicators were 0.921, and the AUC of the three indicators were higher than the single detection <0.05). The sensitivity of CA125 was the highest (69.2%) and the specificity of CA72-4 (88.2%) was the highest in single test. The sensitivities and specificities of the three tests were 81.0% and 84.7% respectively. Conclusion The combined detection of VEGF, CA125 and CA72-4 can effectively improve the diagnostic accuracy of ovarian cancer.